Dare Bioscience reports Q2 2026 results as first direct product launches
The company began selling Flora Sync LF5 in July and reported positive interim Phase 3 data for Ovaprene while starting a Phase 2 study of DARE-HPV.
Dare Bioscience reported financial results for the quarter ended June 30, 2026, on August 13, 2026, alongside a corporate update on its commercial and clinical pipeline. The company launched Flora Sync LF5 through the DARE Health Hub, marking its first direct-to-consumer product offering.1 Dare began recording revenue from Flora Sync LF5 sales in July 2026 and said it expects to start recording revenue from DARE to PLAY Sildenafil Cream sales in the third quarter of 2026.1
For DARE to PLAY, the company said it continued preparing for prescription dispensing, with nationwide prescription intake and early preorder activity underway through the DARE Health Hub.1 Dare also said it entered a strategic collaboration with MyMenopauseRx to connect women interested in DARE to PLAY Sildenafil Cream with a telehealth provider focused on perimenopause and menopause care, aiming to broaden patient access.1
On DARE to RECLAIM, an estradiol and progesterone therapy for menopause, the company said work to support commercial availability through the 503B compounding pathway is underway, with prescription dispensing targeted to begin in 2027.1 Dare is also pursuing an FDA 505(b)(2) regulatory pathway in parallel.1
In the clinical pipeline, Dare reported positive interim results from its ongoing pivotal Phase 3 study of Ovaprene, along with a recommendation from the independent Data Safety Monitoring Board that the study continue without modification.1 With ARPA-H funding, the company initiated a Phase 2 study expected to enroll about 100 women with persistent high-risk HPV infection, with topline results expected in 2027.1 Dare also received a second $1.0 million funding tranche from NIAID, bringing total DARE-HPV program funding since December 2024 to $2.0 million.1
On finances, Dare had approximately $12.6 million in cash and cash equivalents as of June 30, 2026, and a working capital deficit of approximately $0.2 million, which included a deferred grant funding liability of about $15.0 million.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.